Netherlands· NL-bfa37e237d72
KYGEVVI 2 g/2 g poeder voor drank
A doxecitine and doxribtimine product containing doxecitine + doxribtimine, registered in Netherlands by UCB Pharma S.A.. The same ATC class is registered in 9 of our 19 countries.
Checked against CBG-MEB (Netherlands) on
Informational only — not a medical device.
Where it is registered
Doxecitine and doxribtimine is registered in 9 of 19 countries.
Countries holding a registration under ATC A16AX29 (doxecitine and doxribtimine), each read from that country’s own register.
- This record: Netherlands, from CBG-MEB (Netherlands)
- 6 of them publish a price we can compare per daily dose
Doxecitine and doxribtimine · ATC A16AX29
9 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Netherlands
- Polandprice
- United Statesprice
The record
At a glance
CBG-MEB (Netherlands)- Active substance
- DOXECITINE + DOXRIBTIMINE
- Manufacturer
- UCB Pharma S.A.
- Country
- Netherlands (NL)
- ATC code
- A16AX29
- ATC class
- Doxecitine and doxribtimine
- Reimbursed
- Not published by this register
- Source register
- CBG-MEB (Netherlands)
- Last checked
- September 29, 2026
Packs & prices · 1
- cbg_meb_idEU/1/25/2013
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Doxecitine and doxribtimine in 7 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaKYGEVVIUCB Pharma SA, Brusel
- FinlandKYGEVVIUCB Pharma SA
- FranceKYGEVVI 2 g/2 g, poudre pour solution buvableUCB PHARMA BELGIQUE
- IrelandKYGEVVI 2 g/2 g powder for oral solutionUCB Pharma S.A.
- IcelandKYGEVVIUCB Pharma S.A.*
- SwedenKYGEVVI 2 g/2 g Pulver till oral lösningUCB Pharma S.A.
- United StatesKYGEVVIUCB, Inc.
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Kygevvi
- Liechtenstein · Kygevvi
- Norway · Kygevvi
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/b1e47d1f-da0e-4736-999b-21290803d5e5 GET /v1/drugs/b1e47d1f-da0e-4736-999b-21290803d5e5?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Poeder voor drank",
"route": "Oraal gebruik",
"soort": null,
"source": "cbg_meb",
"smpc_url": "https://www.ema.europa.eu/en/documents/product-information/kygevvi-epar-product-information_nl.pdf",
"strength": null,
"atc_label": "Doxecitine and doxribtimine",
"detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/cp134327",
"excipients": [
"MAGNESIUMSTEARAAT (E 470b)",
"SILICIUMDIOXIDE (E 551)"
],
"substances": [
"DOXECITINE",
"DOXRIBTIMINE"
],
"leaflet_url": null,
"authorised_at": "2026/03/26",
"procedure_number": "EMEA/H/C/005119",
"dispensing_status": "Uitsluitend recept",
"registration_number": "EU/1/25/2013",
"additional_monitoring": "Y"
}See everything about doxecitine and doxribtimine.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.